Literature DB >> 6822761

Immunoassays of human prothrombin species which correlate with functional coagulant activities.

R A Blanchard, B C Furie, S F Kruger, G Waneck, M J Jorgensen, B Furie.   

Abstract

Specific immunoassays have been developed for forms of human prothrombin that vary in their degree of carboxylation. Human abnormal (des-gamma-carboxyl) prothrombin was isolated in 18% yield from the plasma of a patient treated with warfarin. The purified protein migrated as a single band in electrophoresis and contained an average of three gamma-carboxyglutamic acid residues per molecule. A specific antibody subpopulation was isolated from rabbit anti-abnormal prothrombin antiserum by using affinity chromatography. These antibodies, which bound to abnormal prothrombin but which cross-reacted minimally with prothrombin, were used to establish an immunoassay specific for abnormal prothrombin. In parallel, a specific antibody subpopulation, anti-prothrombin: Ca(II), was isolated from rabbit anti-prothrombin antiserum by conformation perturbation affinity chromatography. This antibody, which bound prothrombin but minimally cross-reacted with abnormal prothrombin, was used to establish a specific immunoassay for native prothrombin. An anti-prethrombin 1 subpopulation bound abnormal prothrombin and prothrombin equivalently and was used for an immunoassay that measured total prothrombin. These assays permit the quantitation of abnormal prothrombin and prothrombin in plasma and serum. The level of native prothrombin antigen correlates precisely with the functional prothrombin activity. These assays provide an example of the use of specific antibodies against functionally important antigenic surfaces to monitor properties of coagulation proteins with the precision and reliability of immunoassy.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6822761

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  5 in total

1.  The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin.

Authors:  I A Choonara; R G Malia; B P Haynes; C R Hay; S Cholerton; A M Breckenridge; F E Preston; B K Park
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

2.  Immunoaffinity purification of factor IX (Christmas factor) by using conformation-specific antibodies directed against the factor IX-metal complex.

Authors:  H A Liebman; S A Limentani; B C Furie; B Furie
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

3.  Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.

Authors:  R R Sieradzan; W A Bottner; M J Fasco; J S Bertino
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

4.  Molecular basis of hemophilia B: a defective enzyme due to an unprocessed propeptide is caused by a point mutation in the factor IX precursor.

Authors:  D L Diuguid; M J Rabiet; B C Furie; H A Liebman; B Furie
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

5.  Association of congenital deficiency of multiple vitamin K-dependent coagulation factors and the phenotype of the warfarin embryopathy: clues to the mechanism of teratogenicity of coumarin derivatives.

Authors:  R M Pauli; J B Lian; D F Mosher; J W Suttie
Journal:  Am J Hum Genet       Date:  1987-10       Impact factor: 11.025

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.